ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,476.15
0.82%
Dow Jones
38,738.43
0.39%
US Dollar vs MXN
18.50966
0.24%
Brent Oil
83.415
1.57%
Bitcoin
66,431.78
-0.31%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Graphite Bio Inc (GRPH)

  7. Graphite Bio Inc (GRPH) Noticias

GRPH

Graphite Bio (GRPH)

Graphite Bio Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GRPH
FechaHoraFuenteTítuloSímboloCompañía
08/03/202416:17Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:GRPHGraphite Bio Inc
08/03/202416:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GRPHGraphite Bio Inc
08/03/202416:00Business WireGraphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz TherapeuticsNASDAQ:GRPHGraphite Bio Inc
27/02/202415:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:GRPHGraphite Bio Inc
13/02/202415:44Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:GRPHGraphite Bio Inc
09/02/202416:23Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:GRPHGraphite Bio Inc
05/02/202415:31Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRPHGraphite Bio Inc
06/12/202315:57Edgar (US Regulatory)Form S-4 - Registration of securities, business combinationsNASDAQ:GRPHGraphite Bio Inc
15/11/202306:00Business WireLENZ Therapeutics and Graphite Bio Announce Merger AgreementNASDAQ:GRPHGraphite Bio Inc
13/09/202315:06Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:GRPHGraphite Bio Inc
14/08/202316:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GRPHGraphite Bio Inc
21/07/202316:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GRPHGraphite Bio Inc
23/06/202306:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GRPHGraphite Bio Inc
23/06/202306:00Business WireGraphite Bio Announces Departure of Chief Financial OfficerNASDAQ:GRPHGraphite Bio Inc
06/06/202315:16Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:GRPHGraphite Bio Inc
06/06/202315:06Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:GRPHGraphite Bio Inc
11/05/202315:13Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:GRPHGraphite Bio Inc
20/03/202315:18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:GRPHGraphite Bio Inc
20/03/202315:12Edgar (US Regulatory)Annual Report (10-k)NASDAQ:GRPHGraphite Bio Inc
20/03/202315:05Business WireGraphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial ResultsNASDAQ:GRPHGraphite Bio Inc
22/02/202315:05Business WireGraphite Bio Announces Process to Explore Strategic Alternatives and Corporate RestructuringNASDAQ:GRPHGraphite Bio Inc
05/01/202315:05Business WireGraphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell DiseaseNASDAQ:GRPHGraphite Bio Inc
12/12/202207:42Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:GRPHGraphite Bio Inc
11/12/202209:00Business WireGraphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual MeetingNASDAQ:GRPHGraphite Bio Inc
21/11/202207:00Business WireGraphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx ConferenceNASDAQ:GRPHGraphite Bio Inc
13/11/202222:05TipRanksBTIG Sticks to Their Buy Rating for Graphite Bio (GRPH)NASDAQ:GRPHGraphite Bio Inc
13/11/202221:55TipRanksSVB Securities Sticks to Its Buy Rating for Graphite Bio (GRPH)NASDAQ:GRPHGraphite Bio Inc
10/11/202219:49TipRanksGraphite Bio (GRPH) Receives a Hold from RBC CapitalNASDAQ:GRPHGraphite Bio Inc
09/11/202215:05Business WireGraphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial ResultsNASDAQ:GRPHGraphite Bio Inc
03/11/202208:05Business WireGraphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and ExpositionNASDAQ:GRPHGraphite Bio Inc
 Showing the most relevant articles for your search:NASDAQ:GRPH

Su Consulta Reciente

USOTC
RHHBY
Roche (QX)
NYSE
DIS
Walt Disney
USOTC
ADDYY
Adidas (QX)
NYSE
NKE
Nike
AMEX
XLF
Financial Select Sector
SPI
SP500
S&P 500
NASDAQ
TSLA
Tesla
NASDAQ
AAPL
Apple
NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
USOTC
BASFY
BASF (QX)
NYSE
MCD
McDonalds
NYSE
CVX
Chevron
FX
USDMXN
US Dollar vs MXN
NYSE
VZ
Verizon Communications
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados